Market expansion The BeVigilant OraFusion System has already launched in Germany and is CE marked, suggesting an opportunity to pursue additional European market entry and regulatory approvals to broaden adoption among high-risk populations beyond the US.

Regulatory traction FDA Breakthrough Device Designation awards in the past indicate potential for accelerated regulatory pathways and credibility with payers, enabling faster adoption cycles and stronger ROI messaging to clinical buyers.

High risk cohorts Oral cancer risk is concentrated among tobacco users, heavy alcohol consumers, and HPV-16 patients; targeting clinics serving these high-risk populations with point-of-care testing can drive adoption and improve patient outcomes.

Healthcare partnerships With a compact team and a clinician-led leadership group, there is potential to partner with primary care networks, dental/otolaryngology practices, and cancer screening programs to scale deployment and generate recurring revenue through training and service contracts.

Clinical evidence The system measures tumor-initiating and stem cell biomarkers, a clinically validated approach; leveraging published studies and real-world outcomes can strengthen sales pitches to hospitals and referral networks seeking early detection capabilities.